Literature DB >> 26339386

Period 1 and estrogen receptor-beta are downregulated in Chinese colon cancers.

Yupeng Wang1, Tonghai Xing1, Li Huang1, Guohe Song1, Xing Sun1, Lin Zhong1, Junwei Fan1, Dongwang Yan1, Chongzhi Zhou1, Feifei Cui1, Fudong Yu1, Jian Chen1, Yang Yu1, Chao Li1, Huamei Tang2, Zhihai Peng1, Xiaoliang Wang1.   

Abstract

To investigate whether Period 1 (PER1) and Estrogen receptor-beta (ER2) are associated with occurrence and development of Chinese colorectal cancers. By using RT-quantitative PCR, tissue microarray (TMA) and immunohistochemistry, we detected mRNA levels and protein levels of PER1 and ER2 in the cancerous tissues and paired normal adjacent tissues in patients with colorectal cancer. Survival analyses were performed by the Kaplan-Meier method utilizing log-rank test and univariate and multivariate Cox proportional modeling to measure 5-year disease-free survival (DFS) and overall survival (OS). Real-time PCR showed that, the delta Ct value (tumor tissue vs. normal mucosa) of PER1 or ER2 is 8.51 ± 2.81 vs. 7.34 ± 2.08 or 12.39 ± 2.43 vs. 9.76 ± 1.75, expression of PER1 and ER2 decreased significantly in tumor tissues compared with noncancerous mucosas of patients with or without metastasis (both of P values <0.001). Spearman test revealed that PER1 and ER2 were significantly down-regulated in cancerous tissues (r=0.283; P<0.001) which was also confirmed by immunohistochemistry of specimens from 203 colon cancer patients in a TMA format. The reduction of PER1 was associated with gender and distant metastasis (P=0.037 and P<0.001, respectively) whereas the decline of ER2 was associated with age (P=0.043) by analyzing the clinical data. However, we were not capable of detecting any association between PER1 level or ER2 level and overall survival (OS) or disease free survival (DFS). It is the first observation of correlated reduction of PER1 and ER2 in Chinese colon cancers, and they do play a certain role in colorectal cancer.

Entities:  

Keywords:  Period 1; chronotherapy; colon Cancer; estrogen receptor-beta; prognosis

Mesh:

Substances:

Year:  2015        PMID: 26339386      PMCID: PMC4555714     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

1.  Circadian clock and cancer therapy: an unexpected journey.

Authors:  Roman Kondratov
Journal:  Ann Med       Date:  2014-06       Impact factor: 4.709

2.  Changing patterns of colorectal cancer in China over a period of 20 years.

Authors:  Ming Li; Jin Gu
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

3.  CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma.

Authors:  D Nojima; L C Li; A Dharia; G Perinchery; L Ribeiro-Filho; T S Yen; R Dahiya
Journal:  Cancer       Date:  2001-10-15       Impact factor: 6.860

4.  The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells.

Authors:  Sigal Gery; Naoki Komatsu; Lilit Baldjyan; Andrew Yu; Danielle Koo; H Phillip Koeffler
Journal:  Mol Cell       Date:  2006-05-05       Impact factor: 17.970

Review 5.  Reflections on the discovery and significance of estrogen receptor beta.

Authors:  Konrad F Koehler; Luisa A Helguero; Lars-Arne Haldosén; Margaret Warner; Jan-Ake Gustafsson
Journal:  Endocr Rev       Date:  2005-04-27       Impact factor: 19.871

6.  Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer.

Authors:  Sigal Gery; Naoki Komatsu; Norihiko Kawamata; Carl W Miller; Julian Desmond; Renu K Virk; Alberto Marchevsky; Robert Mckenna; Hirokuni Taguchi; H Phillip Koeffler
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531

7.  Expression levels of estrogen receptor beta are modulated by components of the molecular clock.

Authors:  Wen Cai; Juliette Rambaud; Michèle Teboul; Ingrid Masse; Gerard Benoit; Jan-Ake Gustafsson; Franck Delaunay; Vincent Laudet; Ingemar Pongratz
Journal:  Mol Cell Biol       Date:  2007-11-26       Impact factor: 4.272

8.  Role of estrogen receptor beta in colonic epithelium.

Authors:  Osamu Wada-Hiraike; Otabek Imamov; Haruko Hiraike; Kjell Hultenby; Thomas Schwend; Yoko Omoto; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

9.  Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors.

Authors:  Walter Krugluger; Anita Brandstaetter; Enikö Kállay; Johann Schueller; Elisabeth Krexner; Stefan Kriwanek; Elisabeth Bonner; Heide S Cross
Journal:  Cancer Res       Date:  2007-08-15       Impact factor: 12.701

10.  Deregulated expression of circadian clock genes in gastric cancer.

Authors:  Ming-Luen Hu; Kun-Tu Yeh; Pai-Mei Lin; Cheng-Ming Hsu; Hui-Hua Hsiao; Yi-Chang Liu; Hugo You-Hsien Lin; Sheng-Fung Lin; Ming-Yu Yang
Journal:  BMC Gastroenterol       Date:  2014-04-06       Impact factor: 3.067

View more
  4 in total

1.  Estrogen Receptor Beta Inhibits The Proliferation, Migration, And Angiogenesis Of Gastric Cancer Cells Through Inhibiting Nuclear Factor-Kappa B Signaling.

Authors:  Yiping Zhang; Yahua Wu; Xufeng Zhou; Benyi Yi; Lili Wang
Journal:  Onco Targets Ther       Date:  2019-11-05       Impact factor: 4.147

2.  Low circadian clock genes expression in cancers: A meta-analysis of its association with clinicopathological features and prognosis.

Authors:  Jiangguo Zhang; Hong Lv; Mingzhu Ji; Zhimo Wang; Wenqing Wu
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.240

3.  Period Family of Clock Genes as Novel Predictors of Survival in Human Cancer: A Systematic Review and Meta-Analysis.

Authors:  Fan Deng; Kai Yang; Gang Zheng
Journal:  Dis Markers       Date:  2020-08-10       Impact factor: 3.434

4.  Research progress on circadian clock genes in common abdominal malignant tumors.

Authors:  Sheng-Li Yang; Quan-Guang Ren; Lu Wen; Jian-Li Hu; Heng-Yi Wang
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.